Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Molecules (Basel, Switzerland)|July 2, 2021
Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer AgentsZiad Omran, Chris P Guise, Linwei Chen, et al.
Molecular Cancer|June 14, 2013
Pseudomonas aeruginosa NfsB and nitro-CBI-DEI--a promising enzyme/prodrug combination for gene directed enzyme prodrug therapyLaura K Green, Sophie P Syddall, Kendall M Carlin, et al.
Journal of Medicinal Chemistry|March 10, 2022
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4Min Shao, Xiaojuan Chen, Fang Yang, et al.
Journal of Medicinal Chemistry|January 6, 2026
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired ResistanceShuang Xiang, Xiaojuan Chen, Jieying Lin, et al.
Bioorganic Chemistry|April 19, 2025
Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4Jing Guo, Xiaojuan Chen, Xiaofei Li, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy ApplicationsAmir Ashoorzadeh, Alexandra M Mowday, Christopher P Guise, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family OncogenesAdriana Estrada-Bernal, Anh T Le, Andrea E Doak, et al.
Biochemistry|August 13, 2019
Engineering Escherichia coli NfsB To Activate a Hypoxia-Resistant Analogue of the PET Probe EF5 To Enable Non-Invasive Imaging during Enzyme Prodrug TherapyElsie M Williams, Michelle H Rich, Alexandra M Mowday, et al.
ACS Medicinal Chemistry Letters|April 16, 2021
Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 InhibitorsWuqing Deng, Xiaojuan Chen, Kaili Jiang, et al.
European Journal of Medicinal Chemistry|February 16, 2018
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancerQiuping Xiang, Chao Wang, Yan Zhang, et al.
Pageof 9